RGNX REGENXBIO Inc. Stock Quote

RGNX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	1.20%	Shs Outstand	37.34M	Perf Week	2.94%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-4.56	Insider Trans	-27.62%	Shs Float	31.89M	Perf Month	12.08%
Income	-91.50M	PEG	-	EPS next Q	-0.29	Inst Own	89.90%	Short Float	10.33%	Perf Quarter	70.93%
Sales	144.90M	P/S	13.15	EPS this Y	-194.70%	Inst Trans	0.20%	Short Ratio	7.19	Perf Half Y	23.28%
Book/sh	11.13	P/B	4.34	EPS next Y	-127.30%	ROA	-18.70%	Target Price	60.38	Perf Year	-1.55%
Cash/sh	6.13	P/C	7.89	EPS next 5Y	2.00%	ROE	-21.70%	52W Range	20.03 - 54.97	Perf YTD	6.57%
Dividend	-	P/FCF	-	EPS past 5Y	-68.50%	ROI	-32.50%	52W High	-12.06%	Beta	1.21
Dividend %	-	Quick Ratio	6.10	Sales past 5Y	41.90%	Gross Margin	79.80%	52W Low	141.34%	ATR	2.53
Employees	257	Current Ratio	6.10	Sales Q/Q	572.80%	Oper. Margin	-73.10%	RSI (14)	59.43	Volatility	5.47% 5.17%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	124.10%	Profit Margin	-63.10%	Rel Volume	0.87	Prev Close	49.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 AMC	Payout	-	Avg Volume	458.27K	Price	48.34
Recom	2.10	SMA20	2.73%	SMA50	20.04%	SMA200	36.15%	Volume	398,089	Change	-3.22%

Jan-06-21

Upgrade

Raymond James

Outperform → Strong Buy

$60

Dec-16-20

Initiated

UBS

Buy

$57

Jun-25-20

Resumed

BofA/Merrill

Buy

Jun-25-20

Resumed

BofA/Merrill

Buy

$60

May-13-20

Initiated

RBC Capital Mkts

Sector Perform

$42

Aug-20-19

Upgrade

SVB Leerink

Underperform → Mkt Perform

$38 → $37

Jun-18-19

Reiterated

Chardan Capital Markets

Buy

$145 → $150

Jun-14-19

Resumed

Raymond James

Outperform

Jun-05-19

Reiterated

Chardan Capital Markets

Buy

$127.50 → $145

Feb-25-19

Upgrade

Evercore ISI

In-line → Outperform

Feb-05-19

Upgrade

Raymond James

Outperform → Strong Buy

$94

Dec-17-18

Reiterated

Chardan Capital Markets

Buy

$127.50

Nov-08-18

Reiterated

BofA/Merrill

Neutral

$76 → $84

Aug-08-18

Reiterated

Chardan Capital Markets

Buy

$130 → $127.50

Jul-23-18

Downgrade

BofA/Merrill

Buy → Neutral

Jul-10-18

Reiterated

Chardan Capital Markets

Buy

$90 → $130

May-09-18

Reiterated

Barclays

Overweight

$38 → $48

Apr-09-18

Reiterated

Chardan Capital Markets

Buy

$85 → $90

Mar-12-18

Downgrade

Evercore ISI

Outperform → In-line

Feb-13-18

Initiated

Mizuho

Neutral

$28

Jan-12-21 04:05PM	REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-11-21 07:05AM	REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-10-21 02:17AM	REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Reducing Their Forecasts For Next Year Simply Wall St.
Jan-08-21 07:05AM	REGENXBIO Announces Pricing Of Public Offering Of Common Stock PR Newswire -5.11%
Jan-06-21 04:15PM	This Small Gene Therapy Stock Is Taking On Giants Regeneron, Roche Investor's Business Daily +8.39%
04:01PM	REGENXBIO Announces Proposed Public Offering Of Common Stock PR Newswire
11:13AM	REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program Zacks
07:49AM	3 Top Small-Cap Stocks to Buy in January Motley Fool
Jan-05-21 04:05PM	REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy PR Newswire
Dec-23-20 08:29AM	The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga
Dec-22-20 04:19PM	REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million PR Newswire +5.92%
Dec-18-20 09:17PM	Is RGNX A Good Stock To Buy According To Hedge Funds? Insider Monkey
12:14PM	The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals Zacks
Dec-17-20 09:42AM	4 Biotechs That Could Be Potential Acquisition Targets in 2021 Zacks
Dec-10-20 07:05AM	REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery PR Newswire
Dec-09-20 07:05AM	REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II PR Newswire
Dec-01-20 07:05AM	REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I PR Newswire
Nov-23-20 04:05PM	REGENXBIO to Present at Upcoming Investor Conferences PR Newswire -5.38%
Nov-10-20 07:00AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting PR Newswire
Nov-06-20 10:24AM	REGENXBIO Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Simply Wall St.
Nov-05-20 04:05PM	REGENXBIO to Present at Upcoming Investor Conferences PR Newswire -6.60%
Nov-04-20 07:30PM	Regenxbio Inc. (RGNX) Q3 2020 Earnings Call Transcript Motley Fool +8.26%
07:05PM	Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates Zacks
05:27PM	Recap: Regenxbio Q3 Earnings Benzinga
04:05PM	REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights PR Newswire
02:30PM	REGENXBIO, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 04:05PM	REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights PR Newswire
Oct-27-20 10:36AM	Investors Who Bought REGENXBIO (NASDAQ:RGNX) Shares Five Years Ago Are Now Up 77% Simply Wall St.
07:00AM	REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG PR Newswire
Oct-23-20 02:05PM	7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio InvestorPlace
Oct-06-20 05:43PM	Do Hedge Funds Love Regenxbio Inc (RGNX)? Insider Monkey
Sep-30-20 07:00AM	REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) PR Newswire
Sep-25-20 07:00AM	REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
Sep-14-20 09:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire +6.15%
Sep-09-20 07:05AM	REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery PR Newswire
Sep-02-20 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
Aug-25-20 08:20AM	How Does REGENXBIO's (NASDAQ:RGNX) CEO Salary Compare to Peers? Simply Wall St. +5.70%
07:00AM	REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery PR Newswire
Aug-06-20 06:25PM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM	REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights PR Newswire
Aug-04-20 11:25AM	Did Hedge Funds Make The Right Call On Regenxbio Inc (RGNX) ? Insider Monkey
07:00AM	REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD PR Newswire
Jul-30-20 04:05PM	REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights PR Newswire
Jul-29-20 12:33PM	Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-08-20 07:05AM	REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases PR Newswire
Jun-23-20 07:42PM	Should You Buy Regenxbio Inc (RGNX)? Insider Monkey
Jun-10-20 07:30AM	REGENXBIO to Present at the Raymond James Human Health Innovation Conference PR Newswire
Jun-04-20 08:49AM	Edited Transcript of RGNX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-12-20 09:06AM	REGENXBIO Inc. (NASDAQ:RGNX) Just Released Its First-Quarter Earnings: Here's What Analysts Think Simply Wall St.
May-10-20 03:19PM	Were Hedge Funds Right About Regenxbio Inc (RGNX)? Insider Monkey
May-07-20 08:31PM	Regenxbio Inc. (RGNX) Q1 2020 Earnings Call Transcript Motley Fool
Apr-30-20 04:31PM	REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights PR Newswire
Apr-28-20 05:38PM	REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting PR Newswire -5.57%
12:33PM	Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-27-20 01:55PM	Should REGENXBIO (NASDAQ:RGNX) Be Disappointed With Their 86% Profit? Simply Wall St.
Apr-23-20 09:12AM	Another 140,000 apply for unemployment benefits in D.C., Md. and Va. American City Business Journals
Apr-22-20 06:30AM	REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD PR Newswire +5.02%
Mar-31-20 04:05PM	REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder GlobeNewswire
Mar-13-20 10:02AM	Should You Worry About REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Pay Cheque? Simply Wall St. +5.87%
09:34AM	These local companies took the biggest one-day hits on Wall Street on Thursday American City Business Journals
Mar-09-20 07:00AM	REGENXBIO to Present at the Barclays Global Healthcare Conference PR Newswire -10.24%
02:26AM	Edited Transcript of RGNX earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-20 08:45AM	These local companies have taken the biggest hits on Wall Street during current sell-off American City Business Journals
Feb-26-20 07:15PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights PR Newswire
02:34PM	Novavax is working to advance a potential coronavirus vaccine. So are competitors. American City Business Journals
Feb-25-20 08:10AM	Coronavirus fears lead to Wall Street sell-off. Here are the D.C.-area companies hit the hardest. American City Business Journals -5.39%
Feb-19-20 12:31PM	Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to Decline Zacks
Jan-29-20 07:00AM	REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium 2020 PR Newswire
Jan-28-20 01:12PM	How REGENXBIO Inc. (NASDAQ:RGNX) Can Impact Your Portfolio Volatility Simply Wall St.
Jan-10-20 10:08AM	Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks
Jan-09-20 08:30PM	Edited Transcript of RGNX earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
07:00AM	REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update PR Newswire
Dec-19-19 04:22PM	These Hedge Funds Cashed Out Of Regenxbio Inc (RGNX) Too Early Insider Monkey
Dec-18-19 07:41AM	REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II) PR Newswire
Dec-16-19 09:30AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-19 03:27PM	Top stock picks for 2020: Standout small companies MarketWatch
02:07PM	We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth Simply Wall St.
Dec-04-19 05:00AM	Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018 American City Business Journals
Nov-06-19 04:15PM	The FDA Paused This Biotech's Gene Therapy Study And Shares Tumbled Investor's Business Daily
Nov-05-19 06:25PM	Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights PR Newswire
Nov-02-19 12:00PM	What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One Investor's Business Daily
Oct-31-19 04:30AM	8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 07:05AM	Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector in AAV Gene Therapy Delivery GlobeNewswire -11.96%
Oct-29-19 07:00AM	REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights PR Newswire
Oct-25-19 12:49PM	Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years Simply Wall St. +5.48%
09:36AM	Is Regenxbio Inc (RGNX) Going to Burn These Hedge Funds? Insider Monkey
Oct-17-19 07:00AM	REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress PR Newswire
Oct-15-19 02:48PM	RegenxBio gets positive interim data for eye disease treatment American City Business Journals +8.36%
10:57AM	Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA Zacks
Oct-11-19 07:15PM	REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting PR Newswire
Oct-10-19 10:11AM	Wet AMD Space in Focus: New Drug Approvals & Key Advancements Zacks
Oct-06-19 05:15PM	The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck Benzinga
Oct-02-19 08:31AM	Ultragenyx Gets FDA Approval for Label Expansion of Crysvita Zacks
Oct-01-19 01:43PM	Biotech Roundtable: How to Invest in Medicines Future Barrons.com
Sep-30-19 07:00AM	REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference PR Newswire +6.75%
Sep-19-19 08:29AM	An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued Simply Wall St.
Sep-13-19 08:44AM	REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% Zacks
Sep-09-19 12:58PM	This Rockville biotech has added another deal to its growth plan American City Business Journals

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simpson Curran	Chief Oper. & Tech. Officer	Jan 14	Option Exercise	34.06	11,612	395,498	29,360	Jan 14 06:55 PM
Vasista Vittal	Chief Financial Officer	Jan 14	Sale	50.03	11,093	554,983	113,892	Jan 14 06:53 PM
Simpson Curran	Chief Oper. & Tech. Officer	Jan 14	Sale	50.01	11,612	580,716	17,748	Jan 14 06:55 PM
Simpson Curran	Chief Oper. & Tech. Officer	Jan 12	Option Exercise	19.50	1,700	33,150	19,448	Jan 14 06:55 PM
Christmas Patrick J.	Chief Legal Officer	Jan 12	Option Exercise	19.50	1,378	26,871	17,750	Jan 12 04:48 PM
Simpson Curran	Chief Oper. & Tech. Officer	Jan 12	Sale	50.03	1,700	85,051	17,748	Jan 14 06:55 PM
Vasista Vittal	Chief Financial Officer	Jan 12	Sale	50.01	4,200	210,042	124,985	Jan 14 06:53 PM
Christmas Patrick J.	Chief Legal Officer	Jan 12	Sale	49.15	1,378	67,729	16,372	Jan 12 04:48 PM
Christmas Patrick J.	Chief Legal Officer	Jan 11	Option Exercise	14.02	10,122	141,879	26,494	Jan 12 04:48 PM
Christmas Patrick J.	Chief Legal Officer	Jan 11	Sale	49.08	10,122	496,788	16,372	Jan 12 04:48 PM
Christmas Patrick J.	Chief Legal Officer	Jan 08	Option Exercise	12.10	10,000	121,000	26,372	Jan 12 04:48 PM
Christmas Patrick J.	Chief Legal Officer	Jan 08	Sale	47.06	10,000	470,565	16,372	Jan 12 04:48 PM
Vasista Vittal	Chief Financial Officer	Jan 08	Sale	47.07	5,241	246,715	129,185	Jan 11 04:28 PM
Mills Kenneth T.	President and CEO	Jan 07	Option Exercise	0.85	1,500	1,275	283,484	Jan 11 04:27 PM
Simpson Curran	Chief Oper. & Tech. Officer	Jan 07	Option Exercise	19.50	5,185	101,108	22,933	Jan 11 04:29 PM
Simpson Curran	Chief Oper. & Tech. Officer	Jan 07	Sale	50.01	5,185	259,302	17,748	Jan 11 04:29 PM
Vasista Vittal	Chief Financial Officer	Jan 07	Sale	50.00	10,998	549,900	134,426	Jan 11 04:28 PM
Mills Kenneth T.	President and CEO	Jan 07	Sale	50.01	1,500	75,015	281,984	Jan 11 04:27 PM
Mills Kenneth T.	President and CEO	Dec 28	Option Exercise	0.85	6,500	5,525	247,500	Dec 30 04:23 PM
Mills Kenneth T.	President and CEO	Dec 28	Sale	48.67	6,500	316,334	241,000	Dec 30 04:23 PM
Vasista Vittal	Chief Financial Officer	Dec 24	Sale	50.00	3,376	168,800	133,024	Dec 28 04:18 PM
Mills Kenneth T.	President and CEO	Dec 23	Option Exercise	0.85	4,500	3,825	245,500	Dec 28 04:17 PM
Vasista Vittal	Chief Financial Officer	Dec 23	Sale	50.01	21,124	1,056,411	136,400	Dec 28 04:18 PM
Mills Kenneth T.	President and CEO	Dec 23	Sale	50.00	4,500	225,000	241,000	Dec 28 04:17 PM
Mills Kenneth T.	President and CEO	Dec 16	Option Exercise	0.85	15,000	12,750	256,000	Dec 18 04:20 PM
Mills Kenneth T.	President and CEO	Dec 16	Sale	45.00	15,000	675,000	241,000	Dec 18 04:20 PM
Vasista Vittal	Chief Financial Officer	Dec 11	Sale	40.17	14,916	599,176	157,524	Dec 14 04:20 PM
Mills Kenneth T.	President and CEO	Dec 10	Option Exercise	0.85	4,500	3,825	245,500	Dec 14 04:19 PM
Vasista Vittal	Chief Financial Officer	Dec 10	Sale	40.06	22,584	904,715	172,440	Dec 14 04:20 PM
Mills Kenneth T.	President and CEO	Dec 10	Sale	40.00	4,500	180,000	241,000	Dec 14 04:19 PM
Vasista Vittal	Chief Financial Officer	Jul 15	Option Exercise	13.09	3,259	42,660	209,974	Jul 17 04:22 PM
Vasista Vittal	Chief Financial Officer	Jul 15	Sale	40.10	14,950	599,495	195,024	Jul 17 04:22 PM
Vasista Vittal	Chief Financial Officer	May 11	Option Exercise	13.09	500	6,545	207,215	May 12 04:16 PM
Vasista Vittal	Chief Financial Officer	May 11	Sale	40.00	500	20,000	206,715	May 12 04:16 PM
Vasista Vittal	Chief Financial Officer	May 08	Option Exercise	13.09	2,500	32,725	213,715	May 12 04:16 PM
Vasista Vittal	Chief Financial Officer	May 08	Sale	40.18	7,000	281,260	206,715	May 12 04:16 PM
Vasista Vittal	Chief Financial Officer	Apr 24	Option Exercise	13.09	3,000	39,270	223,215	Apr 27 04:30 PM
Vasista Vittal	Chief Financial Officer	Apr 24	Sale	40.11	12,000	481,320	211,215	Apr 27 04:30 PM
Vasista Vittal	Chief Financial Officer	Apr 23	Option Exercise	13.09	3,000	39,270	223,215	Apr 27 04:30 PM
Vasista Vittal	Chief Financial Officer	Apr 23	Sale	40.00	3,000	120,000	220,215	Apr 27 04:30 PM
Vasista Vittal	Chief Financial Officer	Mar 31	Option Exercise	0.85	10,000	8,500	220,215	Apr 02 04:22 PM
Simpson Curran	SVP, Product Development & CTO	Feb 11	Option Exercise	22.00	6,633	145,926	16,512	Feb 12 04:27 PM
Simpson Curran	SVP, Product Development & CTO	Feb 11	Sale	50.49	12,564	634,411	3,948	Feb 12 04:27 PM
HAYDEN DONALD J JR	Director	Feb 10	Option Exercise	0.85	24,800	21,080	24,800	Feb 12 04:22 PM
Vasista Vittal	Chief Financial Officer	Feb 10	Option Exercise	13.09	3,000	39,270	225,021	Feb 12 04:24 PM
Simpson Curran	SVP, Product Development & CTO	Feb 10	Option Exercise	27.10	31,660	858,098	54,308	Feb 12 04:27 PM
Simpson Curran	SVP, Product Development & CTO	Feb 10	Sale	50.22	44,429	2,231,224	9,879	Feb 12 04:27 PM
Vasista Vittal	Chief Financial Officer	Feb 10	Sale	50.07	14,806	741,352	210,215	Feb 12 04:24 PM
HAYDEN DONALD J JR	Director	Feb 10	Sale	50.11	24,800	1,242,728	0	Feb 12 04:22 PM
HAYDEN DONALD J JR	Director	Feb 05	Option Exercise	0.85	2,000	1,700	2,000	Feb 07 04:19 PM
Simpson Curran	SVP, Product Development & CTO	Feb 05	Option Exercise	18.08	5,137	92,886	28,285	Feb 07 04:23 PM
Simpson Curran	SVP, Product Development & CTO	Feb 05	Sale	50.00	5,637	281,850	22,648	Feb 07 04:23 PM
Vasista Vittal	Chief Financial Officer	Feb 05	Sale	50.00	300	15,000	222,021	Feb 07 04:21 PM
HAYDEN DONALD J JR	Director	Feb 05	Sale	50.00	2,000	100,000	0	Feb 07 04:19 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience